Please login to the form below

Not currently logged in
Email:
Password:

sunitinib

This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

the back of data showing it can improve survival compared to standard front-line drug Sutent (sunitinib) from Pfizer, regardless of PD-L1 expression levels. ... As the first treatment option to increase overall survival for subgroups of patients with

Latest news

More from news
Approximately 3 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    standard of care - Pfizer’s Sutent (sunitinib). ... We beat, if you will, the standard of care, ”said Alexandre, adding: “We are superior to sunitinib, which has been on the market for 10 years.”The study also showed evidence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Summary/transcript. In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Summary/transcript. In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics